NASDAQ:SAGE

Sage Therapeutics - SAGE Stock Forecast, Price & News

$41.91

-1.83 (-4.18%)

(As of 03/30/2023 04:00 PM ET)

Add

Compare

Today's Range: $41.90
▼
$43.97
50-Day Range: $39.56
▼
$46.57
52-Week Range: $27.36
▼
$49.56

Volume: 366,535 shs
Average Volume: 511,642 shs
Market Capitalization: $2.50 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $51.14

Institutional Ownership

Sage Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.31 Rating Score
Upside/Downside: 21.1% Upside
$51.14 Price Target
Short Interest: Bearish
9.66% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.37
Upright™ Environmental Score
News Sentiment: 0.33
Based on 4 Articles This Week
Insider Trading: Selling Shares
$519,394 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($8.11) to ($7.56) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

440th out of 999 stocks

Pharmaceutical Preparations Industry

204th out of 489 stocks

3.2

Analyst's Opinion

Consensus Rating
Sage Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 4 buy ratings, 9 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $51.14, Sage Therapeutics has a forecasted upside of 21.1% from its current price of $42.24.
Amount of Analyst Coverage
Sage Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
9.66% of the float of Sage Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Sage Therapeutics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.
Change versus previous month
Short interest in Sage Therapeutics has recently decreased by 4.82%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Sage Therapeutics does not currently pay a dividend.
Dividend Growth
Sage Therapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Sage Therapeutics has received a 72.37% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Antidepressants" and "Clinical research services for mental health" products. See details.
Environmental Sustainability
The Environmental Impact score for Sage Therapeutics is -1.37.

1.8

News and Social Media Coverage

News Sentiment
Sage Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Sage Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 11 people have searched for SAGE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Sage Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sage Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $519,394.00 in company stock.
Percentage Held by Insiders
Only 4.80% of the stock of Sage Therapeutics is held by insiders.
Percentage Held by Institutions
85.60% of the stock of Sage Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Sage Therapeutics are expected to grow in the coming year, from ($8.11) to ($7.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sage Therapeutics is -4.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sage Therapeutics is -4.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sage Therapeutics has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sage Therapeutics (NASDAQ:SAGE) Stock

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.

Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SAGE Stock News Headlines

March 30, 2023 | marketwatch.com

Essential Tremor Treatment Market Trends, Industry Demand and Scope, Top Players Analysis, Forecast 2023 - 2031

March 29, 2023 | marketwatch.com

Postpartum Depression Treatment Market Top Players By 2031

March 30, 2023 | Weiss Ratings (Ad)

Bank Accounts: Frozen!

In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!

March 26, 2023 | marketwatch.com

Mild Cognitive Impairment Therapeutic Market By 2031

March 22, 2023 | marketwatch.com

Essential Tremor Treatment Market Size by 2031

March 22, 2023 | marketwatch.com

Essential Tremor Treatment Market Key Players and Forecast till 2028

March 22, 2023 | finance.yahoo.com

Sage Therapeutics to Present at the Stifel 2023 CNS Days

March 16, 2023 | finance.yahoo.com

Sage Therapeutics Appoints Jessica Federer to Board of Directors

March 30, 2023 | Stansberry Research (Ad)

The gold catalyst we’ve waited for

If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.

March 13, 2023 | msn.com

Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone

March 9, 2023 | msn.com

What 5 Analyst Ratings Have To Say About Sage Therapeutics

March 8, 2023 | finance.yahoo.com

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

March 8, 2023 | finance.yahoo.com

Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone

March 1, 2023 | finance.yahoo.com

Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

February 22, 2023 | finance.yahoo.com

Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease

February 17, 2023 | markets.businessinsider.com

Bank of America Securities Keeps Their Buy Rating on SAGE Therapeutics (SAGE)

February 17, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and SAGE Therapeutics (SAGE)

February 17, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), SAGE Therapeutics (SAGE) and Karyopharm Therapeutics (KPTI)

February 16, 2023 | marketwatch.com

Postpartum Depression Therapeutics Market is Booming in Near Future 2023-2028 with Top Countries Data

February 16, 2023 | finance.yahoo.com

Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Tops Revenue Estimates

February 15, 2023 | marketwatch.com

Essential Tremor Treatment Market Growth, Business Overview and Forecast to 2028

February 13, 2023 | marketwatch.com

Essential Tremor Treatment Market Size in 2023 | NEWEST REPORT | Touch New Level in Forthcoming year till 2028

February 13, 2023 | msn.com

What To Know Regarding A Potential FDA Approved Drug For Postpartum Depression

February 13, 2023 | msn.com

The top doctor at a $2.7 billion pharma company developing a new depression drug says we may be 'on the cusp' of a new wave of mental-health treatments

February 7, 2023 | msn.com

First pill for postpartum depression could be approved by August: FDA

February 7, 2023 | finance.yahoo.com

Sage and Biogen's NDA for Depression Drug Gets Priority Review

February 7, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Omeros (OMER) and SAGE Therapeutics (SAGE)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SAGE Company Calendar

Last Earnings: 2/16/2023
Today: 3/30/2023
Next Earnings (Estimated): 5/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SAGE
CUSIP: N/A
CIK: 1597553
Web: www.sagerx.com
Phone: (617) 299-8380
Fax: 617-299-8379
Employees: 471
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $51.14
High Stock Price Forecast: $73.00
Low Stock Price Forecast: $37.00
Forecasted Upside/Downside: +21.1%
Consensus Rating: Hold
Rating Score (0-4): 2.31
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.98)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-532,780,000.00
Net Margins: -6,930.97%
Pretax Margin: -6,931.88%
Return on Equity: -37.03%
Return on Assets: -34.65%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.47
Quick Ratio: 13.47

Sales & Book Value

Annual Sales: $7.69 million
Price / Sales: 328.03
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $21.05 per share
Price / Book: 2.01

Miscellaneous

Outstanding Shares: 59,720,000
Free Float: 56,852,000
Market Cap: $2.52 billion
Optionable: Optionable
Beta: 1.15

Key Executives

Barry E. Greene
President, Chief Executive Officer & Director

Kimi E. Iguchi
Chief Financial & Accounting Officer

Al Robichaud
Chief Scientific Officer

Amy Schacterle
Senior VP-Research & Development Strategy

Matt Lasmanis
Chief Technology & Innovation Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SAGE Stock - Frequently Asked Questions

Should I buy or sell Sage Therapeutics stock right now?: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings or view top-rated stocks.
What is Sage Therapeutics' stock price forecast for 2023?: 13 equities research analysts have issued 1-year target prices for Sage Therapeutics' shares. Their SAGE share price forecasts range from $37.00 to $73.00. On average, they predict the company's share price to reach $51.14 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price.
View analysts price targets for SAGE or view top-rated stocks among Wall Street analysts.
How have SAGE shares performed in 2023?: Sage Therapeutics' stock was trading at $38.14 at the beginning of the year. Since then, SAGE stock has increased by 10.5% and is now trading at $42.14.
View the best growth stocks for 2023 here.
When is Sage Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our SAGE earnings forecast.
How were Sage Therapeutics' earnings last quarter?: Sage Therapeutics, Inc. (NASDAQ:SAGE) released its earnings results on Thursday, February, 16th. The biopharmaceutical company reported ($2.47) EPS for the quarter, missing analysts' consensus estimates of ($2.37) by $0.10. The biopharmaceutical company earned $2.87 million during the quarter, compared to the consensus estimate of $1.94 million. Sage Therapeutics had a negative trailing twelve-month return on equity of 37.03% and a negative net margin of 6,930.97%. The firm's quarterly revenue was up 74.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.12) earnings per share.
What ETFs hold Sage Therapeutics' stock?: ETFs with the largest weight of Sage Therapeutics (NASDAQ:SAGE) stock in their portfolio include Psyk Etf (PSYK), AdvisorShares Psychedelics ETF (PSIL), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and WisdomTree U.S. SmallCap Fund (EES).

What other stocks do shareholders of Sage Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).
What is Sage Therapeutics' stock symbol?: Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."
Who are Sage Therapeutics' major shareholders?: Sage Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (3.19%), JPMorgan Chase & Co. (2.37%), Dimensional Fund Advisors LP (2.22%), Geode Capital Management LLC (1.69%), Marshall Wace LLP (1.57%) and The Manufacturers Life Insurance Company (1.05%). Insiders that own company stock include Barry E Greene, Barry E Greene, George Golumbeski, James M Frates and Jeffrey M Jonas.
View institutional ownership trends.
How do I buy shares of Sage Therapeutics?: Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Sage Therapeutics' stock price today?: One share of SAGE stock can currently be purchased for approximately $42.14.
How much money does Sage Therapeutics make?: Sage Therapeutics (NASDAQ:SAGE) has a market capitalization of $2.52 billion and generates $7.69 million in revenue each year. The biopharmaceutical company earns $-532,780,000.00 in net income (profit) each year or ($8.98) on an earnings per share basis.
How many employees does Sage Therapeutics have?: The company employs 471 workers across the globe.
How can I contact Sage Therapeutics?: Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The official website for the company is www.sagerx.com. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at ir@sagerx.com, or via fax at 617-299-8379.

This page (NASDAQ:SAGE) was last updated on 3/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Sage Therapeutics - SAGE Stock Forecast, Price & News

Sage Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Sage Therapeutics (NASDAQ:SAGE) Stock

SAGE Stock News Headlines

SAGE Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SAGE Stock - Frequently Asked Questions

Overall MarketRank^™